

Neurotech to Present at the ASX Small to Mid-Cap Investor Conference

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces an upcoming presentation by Dr Thomas Duthy, Executive Director at the ASX Small and Mid-Cap Conference on 13-14 September 2022.

The presentation will be on Wednesday, 14 September 2022 at 11.30am AEST (Sydney) time. Investors who wish to register for the event can do so at the following link: <https://asx.delegateconnect.co/>.

The ASX Small and Mid-Cap Conference is a bi-annual event established in 2018 to support and promote ASX-listed companies in their capital market interface. The conference showcases quality ASX-listed companies to our vast network of Australian investors. The conference sees over 20 ASX-listed companies present their vision, strategy, and investment proposition to over 2,000 investors via a 15-minute live stream presentation and 15-minutes of Q&A.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders that improve quality of life. Neurotech is currently conducting a world-first clinical trial to assess the potential application of NTI164 for the treatment of Autism Spectrum Disorder (ASD). Results of Phase I/II indicated that 93% of participants had notable improvements relating to the severity of illness with no serious side effects. The next step will be initiation of Phase II/III of the trial to further assess the long-term safety and efficacy of NTI164, with the potential to lead to drug registration. Neurotech is also commercialising *Mente*, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.